TRAW TRAW
Company Profile ↓Company Overview
TRAW (TRAW) is a publicly traded company listed on with a market capitalization of $4.99M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Trades at an undemanding P/E of 0.7.
Recent Developments
- Dec 2025 Revenue of $2.79M (+1134.5% YoY); net profit $9.17M.
- Trailing 12 Months Year-on-year growth — revenue +1134.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 5.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 4.96% |
| 1 Year: | 1,134.51% |
Stock Price Performance
| 1 Year: | -62.06% |
| 6 Months: | -72.85% |
| 3 Months: | -64.94% |
| 1 Month: | -20.87% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)40.13 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 82.3% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2014 | Jun 2014 | Sep 2014 | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 57.00K | - | - | 57.00K | - | 57.00K | 2.73M | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.26M | 3.98M | 4.05M | 7.37M | 6.95M |
| Operating Income | -18.73M | -16.76M | -14.89M | -13.36M | -12.35M | -8.96M | -5.88M | -7.52M | -5.40M | -4.32M | -6.79M | -6.07M | -6.76M | -5.90M | -5.64M | -5.59M | -7.24M | -3.63M | -5.10M | -5.12M | -7.34M | -6.27M | -4.10M | -4.64M | -3.99M | -4.13M | -4.12M | -5.64M | -6.14M | -4.61M | -5.09M | -5.21M | -123.35M | -8.54M | - | -5.20M | -1.25M | -4.05M | -7.37M | -6.95M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -5.20M | -1.25M | -4.04M | -7.32M | -6.90M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 21.49M | -915.00K | -3.96M | -7.44M | -7.11M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -18.68M | -16.75M | -14.88M | - | -12.34M | -8.96M | -5.87M | -7.24M | -5.38M | -1.60M | -8.34M | -2.58M | -6.96M | -5.09M | -4.48M | -5.35M | -7.60M | -3.56M | -4.59M | - | - | - | - | - | - | - | - | - | - | -4.25M | -4.74M | -4.98M | -123.14M | -8.47M | - | 21.49M | -915.00K | -3.96M | -7.44M | -7.11M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.32 | -0.27 | -0.22 | -0.20 | -0.19 | -0.26 | -0.28 | -0.20 | -5.64 | -5.92 | -20.52 | -1.49 | - | 2.09 | -0.11 | -0.34 | - | -0.53 |
| R&D Expense | 14.25M | 12.90M | 11.89M | 10.39M | 9.50M | 6.51M | 5.28M | 5.82M | 5.56M | 3.99M | 4.89M | 4.61M | 5.14M | 4.58M | 4.07M | 3.98M | 4.08M | 3.90M | 3.52M | 3.37M | 4.80M | 4.19M | 1.94M | 1.85M | 1.76M | 2.00M | 2.04M | 3.59M | 4.08M | 2.46M | 2.46M | 1.91M | - | - | - | 2.51M | - | - | - | 4.91M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.49M | 46.19M | 4.75M | 800.00K | 11.46M | 5.55M | 787.00K | 1.23M | 2.18M | 231.00K | - | 226.00K | 226.00K | 226.00K | 2.79M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | 19.85M | 20.52M | 25.14M | 20.66M |
| Operating Income | -27.57M | -22.28M | -62.22M | -63.74M | -23.97M | -23.70M | -25.74M | -23.28M | -21.70M | -24.99M | - | -19.63M | -20.30M | -24.91M | -17.88M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | -19.61M | -20.28M | -24.90M | -17.81M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | -18.96M | -18.95M | -166.52M | 9.17M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | - |
| Net Income | -26.29M | -29.91M | -62.54M | -63.68M | -23.98M | -19.67M | -24.09M | -20.57M | -21.50M | -25.16M | - | -18.96M | -18.95M | -166.52M | 9.17M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | -2.17 | - | -22.75 | -22.57 | -35.21 | 0.82 |
| R&D Expense | 22.62M | 52.76M | 50.18M | 49.42M | 25.89M | 20.07M | 19.12M | 16.92M | 15.54M | 16.90M | 7.30M | 11.41M | 11.43M | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 83.85M | 105.15M | 47.34M | 23.45M | 23.23M | 4.98M | 17.92M | 23.67M | 19.99M | - | 39.37M | 22.68M | 24.96M | 10.62M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | 39.35M | 22.66M | 24.95M | 7.98M |
| Cash & Equivalents | 7.34M | 2.71M | 81.53M | 60.01M | 43.58M | 19.80M | 21.40M | - | - | - | - | - | 38.76M | 20.82M | 21.34M | 3.82M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | 29.00K | 18.00K | 1.76M | 3.79M |
| Total Liabilities | - | - | 40.84M | 24.25M | 23.71M | 12.61M | 18.11M | 15.84M | 12.54M | 12.10M | 13.81M | - | 11.06M | 12.01M | 56.59M | 11.25M |
| Current Liabilities | - | - | 25.38M | 10.34M | 10.26M | 7.61M | 10.16M | 9.98M | 8.44M | 8.29M | 10.02M | - | 8.05M | 9.22M | 11.53M | 11.15M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Equity | -108.72M | -138.42M | -158.31M | 80.41M | 22.75M | 10.01M | 4.30M | -11.69M | 5.39M | 11.57M | 6.17M | - | 28.31M | 10.67M | -31.63M | -629.00K |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | 837.04K | 840.14K | 3.65M | 9.07M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | -15.81M | -23.82M | -22.70M | -20.83M | -23.07M | - | -16.29M | -17.93M | -29.79M | -18.18M |
| Investing Cash Flow | - | - | - | - | - | - | - | -55.00K | -15.00K | - | 0 | -14.00K | -3.65M | -2.58M |
| Financing Cash Flow | - | - | - | - | 17.42M | 6.36M | 35.66M | 26.65M | 19.36M | - | 0 | 0 | 33.98M | 3.20M |
| Capital Expenditure | -256.00K | -279.00K | -609.00K | -228.00K | - | - | - | -55.00K | -15.00K | - | - | -14.00K | - | -2.58M |
| Free Cash Flow | - | - | - | - | - | - | - | -20.89M | -23.09M | - | -16.29M | -17.95M | -29.79M | -20.77M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | -16.29M | -17.95M | 536.00K | -17.57M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -1,854.3% | -48.2% | -1,309.1% | -7,968.0% | -209.3% | -427.4% | -3,270.3% | -1,895.9% | -994.0% | -10,819.5% | - | -8,684.5% | -8,981.4% | -11,022.1% | -640.7% |
| Net Margin % | -1,768.3% | -64.8% | -1,315.9% | -7,960.3% | -209.3% | -354.6% | -3,061.2% | -1,675.3% | -985.0% | -10,890.5% | - | -8,391.2% | -8,384.1% | -73,682.7% | 328.7% |
| ROE % | 19.0% | 18.9% | -77.8% | -279.9% | -239.6% | -457.7% | 206.1% | -381.9% | -185.8% | -407.4% | - | -67.0% | -177.5% | 526.5% | -1,457.9% |
| ROCE % | - | -38.1% | -65.6% | -171.9% | -151.3% | -181.3% | 515.0% | -245.5% | -141.1% | -250.8% | - | -62.7% | -150.8% | -185.5% | 3,379.0% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TRAW
Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program
Resubmission of updated data package to MHRA, expected in 3Q 2026, to enable Phase 2a human influenza Challenge study to proceedNEWTOWN, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, Traws, the Company), a clinica…
SpaceX initiated, Salesforce upgraded: Wall Street's top analyst calls
SpaceX initiated, Salesforce upgraded: Wall Street's top analyst calls
Traws Pharma Shares Slide After UK Regulator Postpones Influenza Study
Traws Pharma (NASDAQ:TRAW) shares fell sharply in premarket trading on Monday after the company revealed that UK regulators had delayed a planned mid-stage clinical trial for its influenza treatment candidate. The setback adds to previous r…
Why Did TRAW Stock Slump 28% After Hours?
Traws is delaying a planned human study of its lead flu treatment, tivoxavir marboxil, after feedback from a UK regulator.
Traws Pharma Provides Regulatory Update on Influenza Program
NEWTOWN, Pa., June 12, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral threats, today announced that the planned test o…
Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks
Broad-spectrum antiviral agent with potential utility against Hantavirus, Ebola and Lassa Utilizing a novel dual-strike mechanism, the proprietary combination agent has the potential to deliver a low pill burden option to manage existing an…
TRAW — Frequently Asked Questions
What is the current share price of TRAW?
As of 2026-08-05 17:25 PDT, TRAW trades at $0.55 on NASDAQ/NYSE. Its 52-week range is $0.44 to $3.13.
What is the market capitalisation of TRAW?
TRAW has a market capitalisation of $4.99M on NASDAQ/NYSE.
What is the P/E ratio of TRAW?
TRAW trades at a trailing price-to-earnings (P/E) ratio of 0.67. Its price-to-book (P/B) ratio is -7.93.
Is TRAW a good stock to buy?
This page provides a data-driven analysis of TRAW, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.